|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2018-176, NU 2024-250, NU 2025-038)
INVENTORS
Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry)
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer)...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Immunotherapy, Melanoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Gary Schiltz (PI)*
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate cancer.
BACKGROUND
Current cancer treatments, especially for MLL-rearranged leukemia and prostate cancer, face challenges of off-target effects and...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Targeted Therapy for Glioblastoma via Purine Metabolism Modulation
NU 2019-086
INVENTORS
Atique Ahmed*
Cheol Park
Jack Shireman
SHORT DESCRIPTION
This technology introduces a targeted approach for glioblastoma treatment that modulates purine biosynthesis by targeting the ARL13B-IMPDH2 interaction using repurposed FDA-approved and internationally-used drugs.
BACKGROUND
Glioblastoma is an incurable, aggressive...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Repurposed Drugs, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Compositions and Methods for the Treatment of Intestinal Inflammation
NU 2021-252
INVENTORS
Matthew Bury
Muthukumar Gunasekaran
Sunjay Kaushal
Arun Sharma*
Tiffany Sharma
BACKGROUND
Crohn’s Disease (CD) is partly caused by a highly pro-inflammatory lesion microenvironment which subsequently causes numerous clinical complications. Northwestern University scientists have developed a method to control...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cell therapy, IBD - Inflammatory bowel disease, Immunotherapy, Infectious disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Therapy for acute kidney injury
NU 2022-202
INVENTORS
Pinelopi Kapitsinou*
Ratnakar Tiwari
SHORT DESCRIPTION
Inhibition of MCT4 slows the progression of acute kidney inury to chronic kidney disease
BACKGROUND
Acute kidney inury (AKI) is a sudden onset of kidney dysfunction, often caused by factors such as ischemia, toxins, or infections, leading to impaired filtration and accumulation...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Inflammation, Renal Disease, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137
INVENTORS
Derek Wainwright*
Gary Schiltz
SHORT DESCRIPTION
IDO-PROTAC that target immunosuppressive IDO activity via degradation
ABSTRACT
The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy,chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Immunotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|